Valuation: Alkermes plc

Capitalization 5.11B 4.94B 4.64B 4.12B 7.31B 448B 8.16B 55.85B 20.75B 184B 19.15B 18.76B 772B P/E ratio 2024 *
16.4x
P/E ratio 2025 * 28.1x
Enterprise value 4.82B 4.66B 4.39B 3.89B 6.91B 423B 7.7B 52.73B 19.59B 174B 18.08B 17.72B 729B EV / Sales 2024 *
3.2x
EV / Sales 2025 * 3.39x
Free-Float
90.58%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+0.57%
1 week+0.13%
Current month+0.13%
1 month+11.08%
3 months+9.39%
6 months+21.10%
Current year+9.77%
More quotes
1 week
30.51
Extreme 30.51
31.85
1 month
27.70
Extreme 27.7
32.17
Current year
27.70
Extreme 27.7
32.17
1 year
22.90
Extreme 22.9
32.88
3 years
21.75
Extreme 21.75
33.71
5 years
11.98
Extreme 11.98
33.71
10 years
11.98
Extreme 11.98
80.71
More quotes
Director TitleAgeSince
Chief Executive Officer 63 1991-01-31
Director of Finance/CFO 52 2024-01-31
Chief Tech/Sci/R&D Officer - -
Manager TitleAgeSince
Chairman 63 2011-08-31
Director/Board Member 73 2016-05-25
Director/Board Member 62 2018-03-29
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi.($)
+0.57%+0.13%+15.56%+33.94% 5.11B
-1.50%+3.75%+35.87%-3.30% 47.96B
-0.87%+3.37%-4.61%-18.56% 36.65B
-0.77%-0.06%+5.00%+22.20% 26.22B
-1.27%-2.82%-30.53%-30.59% 15.97B
-1.71%-0.99%+63.75%+69.66% 15.52B
-3.01%-17.30%-62.70%-80.13% 12.55B
-2.93%-1.01%+7.15%-31.33% 11.51B
-1.90%+1.42%+8.49%+98.15% 10.98B
+6.11%+20.16% - - 10.86B
Average -0.73%+0.88%+4.22%+6.67% 19.33B
Weighted average by Cap. -1.00%+1.57%+9.06%+1.22%
See all sector performances

Financials

2024 *2025 *
Net sales 1.51B 1.46B 1.37B 1.21B 2.16B 132B 2.41B 16.47B 6.12B 54.2B 5.65B 5.53B 228B 1.41B 1.36B 1.28B 1.14B 2.02B 124B 2.25B 15.41B 5.73B 50.72B 5.29B 5.18B 213B
Net income 327M 316M 297M 263M 468M 28.63B 521M 3.57B 1.33B 11.75B 1.22B 1.2B 49.37B 182M 176M 166M 147M 261M 15.99B 291M 1.99B 741M 6.56B 683M 670M 27.56B
Net Debt -285M -275M -259M -230M -408M -24.98B -455M -3.11B -1.16B -10.25B -1.07B -1.05B -43.08B -323M -312M -293M -260M -462M -28.3B -515M -3.53B -1.31B -11.61B -1.21B -1.19B -48.8B
More financial data * Estimated data
Logo Alkermes plc
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
Employees
2,100
Calendar
More about the company
Date Price Change Volume
25-02-07 31.57 $ +0.57% 2,081,743
25-02-06 31.39 $ -0.25% 1,468,272
25-02-05 31.47 $ +0.54% 1,150,559
25-02-04 31.30 $ +1.76% 1,131,837
25-02-03 30.76 $ -2.44% 1,270,315

Delayed Quote Nasdaq, February 07, 2025 at 04:00 pm

More quotes
Trading Rating
Investor Rating
ESG MSCI
A
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
31.57USD
Average target price
34.38USD
Spread / Average Target
+8.92%
Consensus

Quarterly revenue - Rate of surprise